You are here
NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.
If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).
PA-18-928 : Innovative Technologies for HIV Behavioral and Social Science Research (R43/R44 Clinical Trial Optional)Release Date: 09-19-2018Open Date: 12-05-2018 Due Dates: Multiple Close Date: 09-05-2021
Background Technology-enabled HIV research has emerged in the past decade as a dynamic field that offers potential to bring HIV prevention and treatment efforts to scale. Technological innovations can help to reach vulnerable and at-risk populations such as minorities, adolescents, older adults, and individuals from rural settings who have challenges accessing conventional prevention and treatmen ...SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
PA-18-708 : Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R43/R44 Clinical Trial Not Allowed)Release Date: 03-15-2018Open Date: 08-05-2018 Due Dates: Multiple Close Date: 09-05-2021
Background G-protein coupled receptor proteins (GPCRs) are membrane bound proteins that serve to modulate cellular activities. Many of the GPCRs have potential significance in healthy mental function and in mental disorders, including receptors for most neurotransmitters and neuropeptides. Drugs targeting GPCRs are currently used in the treatment of mental disorders such as schizophrenia, anxie ...SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health